CS-526
| Code | Size | Price |
|---|
| TAR-T27092-5mg | 5mg | £1,171.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27092-50mg | 50mg | £2,303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27092-100mg | 100mg | £3,042.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CS-526 is a proton pump inhibitor. The inhibitory mechanism of CS-526 on H+,K+-ATPase was a competitive antagonism to the K+ binding site of H+,K+-ATPase, and it was also a reversible inhibition. CS-526 has a potent antisecretory effect on gastric acid secretion without rebound gastric hypersecretion. CS-526 inhibited acute gastric mucosal lesions. CS-526 inhibited histamine-stimulated gastric acid secretion in a dose- and retention time-dependent manner.
CAS:
313272-12-7
Formula:
C20H22FN3O
Molecular Weight:
339.414
Purity:
0.98
SMILES:
C[C@H]1C[C@@H]1Cn1c(C)c(C)c2cnnc(OCc3ccc(F)cc3)c12
References
1. De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanelli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015 Nov;17(11):1124-32. doi: 10.1002/ejhf.339. Epub 2015 Sep 4. PubMed PMID: 26339723.
2. Ito K, Kinoshita K, Yamamura N, Tomizawa A, Inaba F, Morikawa-Inomata Y, Tabata K, Shibakawa N. Pharmacodynamic and pharmacokinetic evaluation of CS-526 in cynomolgus monkeys. Biol Pharm Bull. 2009 Dec;32(12):2010-7. PubMed PMID: 19952420.
3. Ito K, Kinoshita K, Tomizawa A, Morikawa-Inomata Y, Inaba F, Fujita Y, Tabata K, Shibakawa N. The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyr rolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats. J Pharmacol Exp Ther. 2008 Jul;326(1):163-70. doi: 10.1124/jpet.108.137299. Epub 2008 Apr 14. PubMed PMID: 18411413.
4. Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, Shibakawa N. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther. 2007 Oct;323(1):308-17. Epub 2007 Jul 13. PubMed PMID: 17630360.